<VariationArchive VariationID="3255220" VariationName="NM_001429.4(EP300):c.4408dup (p.Met1470fs)" VariationType="Duplication" Accession="VCV003255220" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-29" DateCreated="2024-07-23" MostRecentSubmission="2024-07-23">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="3413990" VariationID="3255220">
      <GeneList>
        <Gene Symbol="EP300" FullName="E1A binding protein p300" GeneID="2033" HGNC_ID="HGNC:3373" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41092592" stop="41180077" display_start="41092592" display_stop="41180077" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41488613" stop="41576080" display_start="41488613" display_stop="41576080" Strand="+" />
          </Location>
          <OMIM>602700</OMIM>
          <Haploinsufficiency last_evaluated="2013-03-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=EP300">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2013-03-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=EP300">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_001429.4(EP300):c.4408dup (p.Met1470fs)</Name>
      <CanonicalSPDI>NC_000022.11:41170520:AAAAAAA:AAAAAAAA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>22q13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41170520" stop="41170521" display_start="41170520" display_stop="41170521" variantLength="1" positionVCF="41170520" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41566524" stop="41566525" display_start="41566524" display_stop="41566525" variantLength="1" positionVCF="41566524" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
      </Location>
      <ProteinChange>M1444fs</ProteinChange>
      <ProteinChange>M1470fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.41566531dup" Assembly="GRCh37">
            <Expression>NC_000022.10:g.41566531dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.41170527dup" Assembly="GRCh38">
            <Expression>NC_000022.11:g.41170527dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009817.1" sequenceAccession="NG_009817" sequenceVersion="1" change="g.82918dup">
            <Expression>NG_009817.1:g.82918dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001362843.2" sequenceAccession="NM_001362843" sequenceVersion="2" change="c.4330dup">
            <Expression>NM_001362843.2:c.4330dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001349772.1" sequenceAccession="NP_001349772" sequenceVersion="1" change="p.Met1444fs">
            <Expression>NP_001349772.1:p.Met1444fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001429.4" sequenceAccession="NM_001429" sequenceVersion="4" change="c.4408dup" MANESelect="true">
            <Expression>NM_001429.4:c.4408dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001420.2" sequenceAccession="NP_001420" sequenceVersion="2" change="p.Met1470fs">
            <Expression>NP_001420.2:p.Met1470fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1422" sequenceAccession="LRG_1422">
            <Expression>LRG_1422:g.82918dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1422t1" sequenceAccession="LRG_1422t1">
            <Expression>LRG_1422t1:c.4408dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1422p1" sequenceAccession="LRG_1422p1" change="p.Met1470fs">
            <Expression>LRG_1422p1:p.Met1470fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001429.4(EP300):c.4408dup (p.Met1470fs) AND Rubinstein-Taybi syndrome due to EP300 haploinsufficiency" Accession="RCV004595403" Version="1">
        <ClassifiedConditionList TraitSetID="6729">
          <ClassifiedCondition DB="MedGen" ID="C3150941">Rubinstein-Taybi syndrome due to EP300 haploinsufficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-12-21" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-12-21" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-07-23" MostRecentSubmission="2024-07-23">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">24381114</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29460469</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32476269</ID>
        </Citation>
        <Citation Type="review" Abbrev="GeneReviews">
          <ID Source="PubMed">20301699</ID>
          <ID Source="BookShelf">NBK1526</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="6729" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15794" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Rubinstein-Taybi syndrome due to EP300 haploinsufficiency</ElementValue>
                <XRef ID="MONDO:0013364" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Rubinstein-Taybi syndrome 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">RSTS2</ElementValue>
                <XRef Type="MIM" ID="613684" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EP300</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Rubinstein-Taybi syndrome (RSTS) is characterized by distinctive facial features, broad and often angulated thumbs and halluces, short stature, and moderate-to-severe intellectual disability. The characteristic craniofacial features are downslanted palpebral fissures, low-hanging columella, high palate, grimacing smile, and talon cusps. Prenatal growth is often normal, then height, weight, and head circumference percentiles rapidly drop in the first few months of life. Short stature is typical in adulthood. Obesity may develop in childhood or adolescence. Average IQ ranges between 35 and 50; however, developmental outcome varies considerably. Some individuals with EP300-RSTS have normal intellect. Additional features include ocular abnormalities, hearing loss, respiratory difficulties, congenital heart defects, renal abnormalities, cryptorchidism, feeding problems, recurrent infections, and severe constipation.</Attribute>
                <XRef ID="NBK1526" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17535" />
                <XRef ID="17535" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301699</ID>
                <ID Source="BookShelf">NBK1526</ID>
              </Citation>
              <XRef ID="353284" DB="Orphanet" />
              <XRef ID="783" DB="Orphanet" />
              <XRef ID="C3150941" DB="MedGen" />
              <XRef ID="MONDO:0013364" DB="MONDO" />
              <XRef Type="MIM" ID="613684" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="9874919" SubmissionDate="2024-07-18" DateLastUpdated="2024-07-23" DateCreated="2024-07-23">
        <ClinVarSubmissionID localKey="vcgs/unit_1/hg38_NM_001429_3_EP300_c_4408dupA" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV005086691" DateUpdated="2024-07-23" DateCreated="2024-07-23" Type="SCV" Version="1" SubmitterName="Victorian Clinical Genetics Services, Murdoch Childrens Research Institute" OrgID="500104" OrganizationCategory="laboratory" OrgAbbreviation="VCGS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20301699</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24381114</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29460469</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32476269</ID>
          </Citation>
          <Comment>Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Rubinstein-Taybi syndrome 2 (RSTS; MIM#613684) and Menke-Hennekam syndrome 2 (MHS2; MIM#618333). Additionally, dominant negative is a suggested mechanism (PMIDs: 20301699, 24381114). Variants reported to cause RSTS are found throughout the protein, whereas of the few variants reported to cause MHS, all were located in exon 31 (PMID: 29460469). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0115 - Variants in this gene are known to have variable expressivity. Clinical features and developmental outcomes vary considerably between individuals with RSTS, with rare reports of pathogenic variants inherited from asymptomatic or mildly affected parents (PMID: 20301699). (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). Functional analysis using western blotting and RT-qPCR showed a decrease in protein and mRNA expression respectively (PMID: 32476269). (SP) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0701 - Other NMD-predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. Many NMD-predicted variants have previously been reported as pathogenic in patients with RSTS (ClinVar). (SP) 0802 - This variant has moderate previous evidence of pathogenicity in unrelated individuals. This variant has been reported as de novo in one individual with EP300-related features (PMID: 32476269). (SP) 0905 - No published segregation evidence has been identified for this variant. (I) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="EP300" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_23491</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001429.3:c.4408dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613684" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_45</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="9874919" TraitType="Disease" MappingType="XRef" MappingValue="613684" MappingRef="OMIM">
        <MedGen CUI="C3150941" Name="Rubinstein-Taybi syndrome due to EP300 haploinsufficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

